NASDAQ:AGLE Aeglea BioTherapeutics (AGLE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$9.47▼$13.7652-Week Range N/AVolume43,300 shsAverage Volume95,409 shsMarket Capitalization$48.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aeglea BioTherapeutics alerts: Email Address Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Aeglea BioTherapeutics Stock (NASDAQ:AGLE)Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Read More Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade AGLE Stock News HeadlinesFebruary 21, 2024 | benzinga.comNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, PredictionsJanuary 30, 2024 | wsj.comBridge Biotherapeutics Inc.September 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…December 7, 2023 | finance.yahoo.comSpyre Therapeutics Announces $180 Million Private PlacementNovember 27, 2023 | msn.comAeglea Biotherapeutics announces name change to Spyre TherapeuticsNovember 27, 2023 | markets.businessinsider.comAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRENovember 27, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDNovember 9, 2023 | finance.yahoo.comAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 30, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming November Investor ConferencesOctober 5, 2023 | msn.comAeglea BioTherapeutics (AGLE) Price Target Increased by 2435.71% to 18.11October 2, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Grants of Inducement AwardsSeptember 14, 2023 | finance.yahoo.comAeglea BioTherapeutics to Participate in Upcoming September ConferenceSeptember 14, 2023 | markets.businessinsider.comAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel NicolausSeptember 8, 2023 | finanznachrichten.deAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock SplitSeptember 7, 2023 | finance.yahoo.comAeglea BioTherapeutics Announces Reverse Stock SplitSeptember 5, 2023 | seekingalpha.comAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOSeptember 5, 2023 | markets.businessinsider.comAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial OfficerSee More Headlines Receive AGLE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AGLE CUSIPN/A CIK1636282 Webwww.aegleabio.com Phone(512) 942-2935Fax512-872-5121Employees69Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($75.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,820,000.00 Net Margins-22,195.36% Pretax Margin-27,931.12% Return on Equity-132.05% Return on Assets-146.87% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.59 Sales & Book Value Annual Sales$2.33 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($60.61) per share Price / BookN/AMiscellaneous Outstanding Shares4,050,000Free Float3,782,000Market Cap$48.64 million OptionableOptionable Beta2.57 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Jonathan D. Alspaugh M.B.A. (Age 40)Strategic Advisor Comp: $568.55kMr. James Paul Kastenmayer J.D. (Age 51)Ph.D., Consultant Comp: $611.84kDr. Cameron Turtle DPHIL (Age 33)Ph.D., COO & Principal Executive Officer Mr. Scott L. Burrows (Age 46)Chief Financial Officer Joey PerroneVice President of Finance & Investor RelationsMs. Heidy Abreu King-Jones J.D. (Age 40)L.L.M., Chief Legal Officer & Corporate Secretary Dr. Kelly Boothe Ph.D.Senior Director of Corporate Communications & Investor RelationsMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROOvid TherapeuticsNASDAQ:OVIDOrganigramNASDAQ:OGIContext TherapeuticsNASDAQ:CNTXCybinNYSE:CYBNView All Competitors AGLE Stock Analysis - Frequently Asked Questions How were Aeglea BioTherapeutics' earnings last quarter? Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) issued its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($7.75) EPS for the quarter, missing analysts' consensus estimates of ($7.00) by $0.75. The biotechnology company earned $1.40 million during the quarter, compared to analyst estimates of $1.38 million. Aeglea BioTherapeutics had a negative net margin of 22,195.36% and a negative trailing twelve-month return on equity of 132.05%. When did Aeglea BioTherapeutics' stock split? Aeglea BioTherapeutics shares reverse split on the morning of Friday, September 8th 2023. The 1-25 reverse split was announced on Thursday, September 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO? 3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Aeglea BioTherapeutics IPO? Aeglea BioTherapeutics (AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager. What other stocks do shareholders of Aeglea BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO) and Axsome Therapeutics (AXSM). This page (NASDAQ:AGLE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeglea BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
